Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00820989 · ClinicalTrials.gov registry record · Phase 1
Inflammation and the Host Response to Injury (In Healthy Volunteers)
A Phase 1 study of Immune System, sponsored by Rutgers, The State University of New Jersey.
- Completed
- Registry status
- Phase 1
- Development phase
- 116
- Enrollment target
- 1
- Study location
NCT00820989 is a Phase 1 study of Immune System that has completed, run by Rutgers, The State University of New Jersey. The registered enrollment target is 116 participants. The trial reports 1 study location across 1 state.
The verdict
NCT00820989, a Phase 1 study of Immune System, has completed, sponsored by Rutgers, The State University of New Jersey.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 116 participants
- Enrollment target
- 1
- Study location
Study Summary
The body's immune response to injury or infection is very complex.Endotoxin is a man-made substance, which causes the body to "mimic" sickness (fever,chills, and achiness)for a few hours. This study is designed to determine whether certain proteins, genetics, or heart rate variability change affects the body's response to endotoxin.
Conditions Studied
Interventions
- BIOLOGICAL Endotoxin, Lipopolysaccharide, LPS
Study Locations (1)
New Jersey
- Rutgers-RWJMS - New Brunswick
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 116 participants |
| Start Date | 2000-02 |
| Est. Completion | 2011-02 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00820989
The ClinicalTrials.gov registry entry for NCT00820989 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 116 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Rutgers, The State University of New Jersey, which has 413 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Immune System appearing as the primary indexed condition, and to 1 intervention - of which Endotoxin, Lipopolysaccharide, LPS is the first listed.
NCT00820989 reports 1 study location spanning 1 distinct geographic area - top geographies include New Jersey.
Frequently Asked Questions
What is clinical trial NCT00820989 about?
NCT00820989 is a clinical study titled "Inflammation and the Host Response to Injury (In Healthy Volunteers)". The body's immune response to injury or infection is very complex.Endotoxin is a man-made substance, which causes the body to "mimic" sickness (fever,chills, and achiness)for a few hours. This study is designed to determine whether certain proteins, genetics, or heart rate variability change affects...
What is the current status of trial NCT00820989?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 116 participants. The study started on 2000-02. Estimated completion is 2011-02.
What conditions does trial NCT00820989 study?
This clinical trial studies the following conditions: Immune System.
What interventions are being tested in trial NCT00820989?
The interventions under investigation include: Endotoxin, Lipopolysaccharide, LPS (BIOLOGICAL).
Who is sponsoring clinical trial NCT00820989?
This trial is sponsored by Rutgers, The State University of New Jersey, which has 413 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00820989 being conducted?
This trial has 1 study location across New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.